This hypothesis is further supported by our unbiased, high-throughput screen demonstrating that, at least within a T-cell lymphoma context, LAMs are relatively “resistant” to selective CSF1R antagonists, and is compatible with similar findings in other model systems (42, 43). The gene discussed is CSF1R; the disease is T-cell non-Hodgkin lymphoma.